Latest Research And Development News

Chimeric Therapeutics has secured a $1.785 million advance against its anticipated FY26 Research and Development Tax Incentive to bolster its clinical trial pipeline and working capital.

Elixir Energy has reached a key milestone by drilling and casing the heel of its Lorelle-3H well in Queensland’s Taroom Trough, setting the stage for horizontal drilling aimed at unlocking commercial gas flow.

FBR Limited reports a significant reduction in half-year losses alongside new robotic product launches, yet cash flow challenges raise questions about its financial sustainability.

Merino & Co. Limited reported a 60.5% drop in revenue and a 28.2% increase in net loss for the half-year ending December 2025, reflecting a strategic investment phase aimed at future growth. The company is expanding production capacity and building inventory ahead of wholesale expansion, signaling a pivot towards revenue acceleration.

Nanoveu Limited reported a dramatic revenue increase driven by its strategic acquisition of Embedded A.I. Systems, while losses widened as it invests heavily in semiconductor commercialisation. The company’s recent $7.5 million capital raise aims to fuel its next growth phase.

PARKD Limited reported a 37% revenue decline to $3.88 million for H1 FY2026, driven by the winding down of its flagship Audi Centre Myaree project. The company posted a $1.03 million loss as it invests in East Coast growth and commissions a new prefabrication facility in Penrith, NSW.

Argent BioPharma reported a significantly reduced half-year loss of A$2.9 million, progressing a strategic acquisition to bolster its CannEpil drug pipeline and securing up to A$11 million in new funding.

Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.

Avecho Biotechnology reported a 9.3% revenue increase alongside a 41.5% rise in net loss for 2025, while progressing its Phase III CBD insomnia trial and securing a significant licensing agreement with Sandoz.

PainChek Limited reported a half-year loss of AUD 4.7 million but achieved a major regulatory milestone with FDA clearance for its Adult App, unlocking significant US market opportunities. The company also completed a share consolidation and raised capital to support growth.

Radiopharm Theranostics reported a 44% increase in net loss to $27 million for the half-year ended December 2025, driven by expanded R&D spending. The company bolstered its cash reserves through a $35 million placement while progressing multiple clinical trials across its radiopharmaceutical pipeline.

Racura Oncology reported a $4.1 million loss for H1 FY26, reflecting heavy investment in clinical trials and intellectual property. The company also boosted cash reserves through capital raises and rebranded from Race Oncology.